Cancer cell profiling by barcoding allows multiplexed protein analysis in fine needle aspirates

Por Ullal, Adeeti V., Peterson, Vanessa, Agasti, Sarit S., Tuang, Suan, Juric, Dejan, Castro, Cesar M., Weissleder, Ralph
Publicado em 2014

Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies

Por De Buck, Stefan S, Jakab, Annamaria, Boehm, Markus, Bootle, Douglas, Juric, Dejan, Quadt, Cornelia, Goggin, Timothy K
Publicado no Br J Clin Pharmacol (2014)

Cell Atlas of The Human Fovea and Peripheral Retina

Por Yan, Wenjun, Peng, Yi-Rong, van Zyl, Tavé, Regev, Aviv, Shekhar, Karthik, Juric, Dejan, Sanes, Joshua R.
Publicado no Sci Rep (2020)

Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance

Por Wehrenberg-Klee, Eric, Turker, N. Selcan, Heidari, Pedram, Larimer, Benjamin, Juric, Dejan, Baselga, José, Scaltriti, Maurizio, Mahmood, Umar
Publicado no J Nucl Med (2016)

Single-cell barcode analysis provides a rapid readout of cellular signaling pathways in clinical specimens

Por Giedt, Randy J., Pathania, Divya, Carlson, Jonathan C. T., McFarland, Philip J., del Castillo, Andres Fernandez, Juric, Dejan, Weissleder, Ralph
Publicado no Nat Commun (2018)

Cell atlas of aqueous humor outflow pathways in eyes of humans and four model species provides insight into glaucoma pathogenesis

Por van Zyl, Tavé, Yan, Wenjun, McAdams, Alexi, Peng, Yi-Rong, Shekhar, Karthik, Regev, Aviv, Juric, Dejan, Sanes, Joshua R.
Publicado no Proc Natl Acad Sci U S A (2020)

Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures

Por Juric, Dejan, Sale, Sanja, Hromas, Robert A., Yu, Ron, Wang, Yan, Duran, George E., Tibshirani, Robert, Einhorn, Lawrence H., Sikic, Branimir I.
Publicado em 2005

Amplification of Whole Tumor Genomes and Gene-by-Gene Mapping of Genomic Aberrations from Limited Sources of Fresh-Frozen and Paraffin-Embedded DNA

Por Bredel, Markus, Bredel, Claudia, Juric, Dejan, Kim, Young, Vogel, Hannes, Harsh, Griffith R., Recht, Lawrence D., Pollack, Jonathan R., Sikic, Branimir I.
Publicado em 2005

A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types

Por Dinkelborg, Patrick H., Wang, Meng, Gheorghiu, Liliana, Gurski, Joseph M., Hong, Theodore S., Benes, Cyril H., Juric, Dejan, Jimenez, Rachel B., Borgmann, Kerstin, Willers, Henning
Publicado no Breast Cancer Res Treat (2019)

Multi-omics profiling establishes the polypharmacology of FDA Approved CDK4/6 inhibitors and the potential for differential clinical activity

Por Hafner, Marc, Mills, Caitlin Elizabeth, Subramanian, Kartik, Chen, Chen, Chung, Mirra, Boswell, Sarah Ann, Everley, Robert A., Liu, Changchang, Walmsley, Charlotte Sanden, Juric, Dejan, Sorger, Peter Karl
Publicado no Cell Chem Biol (2019)

Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor

Por Harding, James J., Bauer, Todd M., Tan, Daniel S. W., Bedard, Philippe L., Rodon, Jordi, Doi, Toshihiko, Schnell, Christian, Iyer, Varsha, Baffert, Fabienne, Radhakrishnan, Rajkumar, Fabre, Claire, Juric, Dejan
Publicado no Invest New Drugs (2018)

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1

Por Ebi, Hiromichi, Costa, Carlotta, Faber, Anthony C., Nishtala, Madhuri, Kotani, Hiroshi, Juric, Dejan, Della Pelle, Patricia, Song, Youngchul, Yano, Seiji, Mino-Kenudson, Mari, Benes, Cyril H., Engelman, Jeffrey A.
Publicado em 2013

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-specific Inhibitor, with Letrozole in ER+/HER2-Negative Metastatic Breast Cancer

Por Mayer, Ingrid A., Abramson, Vandana G., Formisano, Luigi, Balko, Justin M., Estrada, Mónica V., Sanders, Melinda E., Juric, Dejan, Solit, David, Berger, Michael F., Won, Helen H., Li, Yisheng, Cantley, Lewis C., Winer, Eric, Arteaga, Carlos L.
Publicado no Clin Cancer Res (2016)

Phase I Dose Escalation Study of Taselisib (GDC-0032), an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Por Juric, Dejan, Krop, Ian, Ramanathan, Ramesh K., Wilson, Timothy R., Ware, Joseph A., Sanabria Bohorquez, Sandra M., Savage, Heidi M., Sampath, Deepak, Salphati, Laurent, Lin, Ray S., Jin, Huan, Parmar, Hema, Hsu, Jerry Y., Von Hoff, Daniel D., Baselga, Jose
Publicado no Cancer Discov (2017)

Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer: A Phase 1b Clinical Trial

Por Juric, Dejan, Janku, Filip, Rodón, Jordi, Burris, Howard A., Mayer, Ingrid A., Schuler, Martin, Seggewiss-Bernhardt, Ruth, Gil-Martin, Marta, Middleton, Mark R., Baselga, José, Bootle, Douglas, Demanse, David, Blumenstein, Lars, Schumacher, Karl, Huang, Alan, Quadt, Cornelia, Rugo, Hope S.
Publicado no JAMA Oncol (2018)

FGFR1 gene amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor positive (HR+) breast cancer

Por Drago, Josh, Formisano, Luigi, Juric, Dejan, Niemierko, Andrzej, Servetto, Alberto, Wander, Seth, Spring, Laura, Vidula, Neelima, Peppercorn, Jeffrey, Younger, Jerry, Malvarosa, Giuliana, Yuen, Megan, Sgroi, Dennis, Isakoff, Steven J., Moy, Beverly, Ellisen, Leif W., Iafrate, John, Arteaga, Carlos L., Bardia, Aditya
Publicado no Clin Cancer Res (2019)

A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies

Por Juric, Dejan, de Bono, Johann S., LoRusso, Patricia M., Nemunaitis, John, Heath, Elisabeth I., Kwak, Eunice L., Mercadé, Teresa Macarulla, Geuna, Elena, Jose de Miguel-Luken, Maria, Patel, Chirag, Kuida, Keisuke, Sankoh, Serap, Westin, Eric H., Zohren, Fabian, Shou, Yaping, Tabernero, Josep
Publicado no Clin Cancer Res (2017)

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

Por Juric, Dejan, Dienstmann, Rodrigo, Cervantes, Andres, Hidalgo, Manuel, Messersmith, Wells, Blumenschein, George R., Tabernero, Josep, Roda, Desamparados, Calles, Antonio, Jimeno, Antonio, Wang, Xiaodong, Bohórquez, Sandra Sanabria, Leddy, Cecilia, Littman, Catherine, Kapp, Amy V., Shames, David S., Penuel, Elicia, Amler, Lukas C., Pirzkall, Andrea, Baselga, José
Publicado no Clin Cancer Res (2015)

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

Por Juric, Dejan, Rodon, Jordi, Tabernero, Josep, Janku, Filip, Burris, Howard A., Schellens, Jan H.M., Middleton, Mark R., Berlin, Jordan, Schuler, Martin, Gil-Martin, Marta, Rugo, Hope S., Seggewiss-Bernhardt, Ruth, Huang, Alan, Bootle, Douglas, Demanse, David, Blumenstein, Lars, Coughlin, Christina, Quadt, Cornelia, Baselga, José
Publicado no J Clin Oncol (2018)

CDK 4/6 inhibitors sensitize PIK3CA Mutant Breast Cancer to PI3K inhibitors

Por Vora, Sadhna R., Juric, Dejan, Kim, Nayoon, Mino-Kenudson, Mari, Huynh, Tiffany, Costa, Carlotta, Lockerman, Elizabeth L., Pollack, Sarah F., Liu, Manway, Li, Xiaoyan, Lehar, Joseph, Wiesmann, Marion, Wartmann, Markus, Chen, Yan, Cao, Z. Alexander, Pinzon-Ortiz, Maria, Kim, Sunkyu, Schlegel, Robert, Huang, Alan, Engelman, Jeffrey A.
Publicado em 2014